Cage Bio
San Carlos, US · Founded 2016 · Delaware corporation
CAGE Bio is a clinical-stage biotech developing localized topical treatments for dermatology, inflammation, and immunology conditions using its proprietary deep eutectic ionic liquid platform. The technology enables small and large molecules such as proteins and nucleic acids to penetrate the skin, aiming to match the efficacy of systemic drugs while avoiding their side effects.
BiotechDeep TechDigital Health
Founders & leadership
NJ
Nitin JoshiNamed on SEC filing
SM
Samir MitragotriNamed on SEC filing
RS
Ravi SrinivasanNamed on SEC filing
Board
JK
Jeff KeyserBoard director
Reported raises · per SEC filings
Form D private placements$28.8M disclosed across 3 rounds · 2019–2024
▶$11MraisedApr 2025 · 14 investors · OtherRule 506(b)
▶$11MraisedApr 2025 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Nitin JoshiExecutive Officer, Director
- Jeff KeyserDirector
- Samir MitragotriDirector
- Offering amount
- $15M
- Amount sold
- $11M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedOct 2021 · 4 investors · PharmaceuticalsRule 506(b)
▶$8.5MraisedOct 2021 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nitin JoshiExecutive Officer, Director
- Ravi SrinivasanDirector
- Samir MitragotriDirector
- Offering amount
- $15M
- Amount sold
- $8.5M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$9.4MraisedFeb 2021 · 56 investors · PharmaceuticalsRule 506(b)
▶$9.4MraisedFeb 2021 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ravi SrinivasanExecutive Officer, Director
- Samir MitragotriDirector
- Nitin JoshiExecutive Officer, Director
- Offering amount
- $9.8M
- Amount sold
- $9.4M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapJucaBio10 shared keywordsJucaBio is a privately held, clinical-stage biopharmaceutical company using a hub-and-spoke model to acquire differentiated drug assets and build subsidiaries that run focused clinical development programs. It targets drugs addressing significant unmet medical needs.
Legend Biotech6 shared keywordsLegend Biotech is a biotechnology company. The provided page content is an external-link disclaimer and contains no substantive information about the company's products or business.
Coya Therapeutics5 shared keywords
GentiBio5 shared keywordsGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Companies competing with Cage Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cage Bio do?
- CAGE Bio is a clinical-stage biotech developing localized topical treatments for dermatology, inflammation, and immunology conditions using its proprietary deep eutectic ionic liquid platform. The technology enables small and large molecules such as proteins and nucleic acids to penetrate the skin, aiming to match the efficacy of systemic drugs while avoiding their side effects.
- How much funding has Cage Bio raised?
- Cage Bio has disclosed $28.8M raised across 3 rounds.
- Where is Cage Bio headquartered?
- Cage Bio is headquartered in San Carlos, US.